NewswireToday - /newswire/ -
Stockholm, Södermanland, Sweden, 2011/09/20 - Attana and Layerlab announced that they have signed a global distribution agreement under which Attana will distribute memLAYER™ for utilization together with Attana’s QCM biosensors - Attana.com.
memLAYER™, one of Layerlab’s core products, is a chemistry kit that provides biosensor users with a unique approach of immobilizing biological membranes to biosensor surfaces. This enables easier analysis of membrane protein functionality, saving both time and money in the process of drug development.
“Attana is continually striving for collaborations that lead to innovative and efficient applications for our customers. Layerlab’s immobilization technology compliments Attana’s biosensors and offers our customers easier and faster applications for studies of molecular interactions.” says Teodor Aastrup, CEO and founder of Attana.
”Attana is a considerable actor on the biosensor market and we are pleased that memLAYER™ will now be utilized on Attana’s QCM biosensors. The collaboration will lead to increased areas of use for memLAYER™ and supports our strategi to globally increase our local presence on the biosnesor market.” says Torbjörn Pettersson CEO Layerlab AB.
About Layerlab AB
Layerlab AB is a biotech-tools company with focus on biosensing to widen the usability of biosensors and biosensor-based applications. The company has developed proprietary technologies for analyzing membrane proteins and membrane processes in its product area memLAYER™, as well as z-LAB™ that is a complete, real-time, label-free instrument for in-depth surface impedance analysis with applications in life science. The company was founded in 2002 and is based on technologies developed at Chalmers Technical University Gothenburg, Sweden.
About Attana AB
Founded in 2002, based in Stockholm, Sweden, Attana AB develops biosensors for the pharmaceutical, diagnostic and academic society worldwide. With a strong focus on characterizing molecular interactions exactly as they occur in the human body, Attana is committed to increasing the success of clinical trials by providing the life science community with biologically relevant information.
Attana’s biosensors can be used to determine specificity, kinetics and affinity, amongst other binding characteristics of biomolecules and macrostructures of varying species such as cells, antibodies, proteins, viruses and bacteria.